Stem cells in predictive toxicology
Availability of validated human cell-based in vitro toxicity screens may facilitate earlier attrition of compounds with…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
New second-line drug for type II diabetes results in less hypoglycaemia: The Lancet
According to a report published in The Lancet, a new drug could offer significant advantages over existing treatments for type II…
Imminent patent expiry of key blockbusterdDrugs to benefit generics manufacturers: Frost &…
The balance in terms of healthcare expenditure and sales revenue is poised to shift from developed to emerging markets
Mylan confirms first-to-file patent challenge relating to Pristique tablets
Pfizer, Wyeth, Wyeth Pharmaceuticals, and PF Prism CV sues Mylan
Drug pricing norms: Cost or MRP based?
As the second largest exporter of bulk drugs and largest formulation exporter, the Indian pharmaceutical industry has made its…
Venus Remedies: Reinventing R&D
Generic dominated Indian pharma market also has exceptions like Venus Remedies who wants to make transition from generic to…
Regulatory woes of pharma SMEs (Part I)
Jagmohan Rai Agarwal has experienced the workings of the Indian drug regulatory authorities across the country while engaged in…
Back to the roots Landscaping OTC opportunities in the Indian ayurveda market
Sreedevi Yallamrazu, Senior Strategic Analyst, CubeX comments on the acceptance of traditional medicine for holistic health and…
A holistic view of the HPAPI opportunity
The High Potency Active Pharmaceutical Ingredients (HPAPI) segment is the potential cash cow of the pharma procurement basket but…
Beyond the Ban
The Government of India (GOI) recently banned the use of serology-based test kits for diagnosis of tuberculosis. But this will…